XGN
Exagen Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$7.58
+0.53%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 71.1M | 66.6M | 55.6M | 52.5M | 45.6M |
| Cost of Revenue | 29.4M | 27.8M | 22.5M | 23.1M | 24.2M |
| Gross Profit | 41.7M | 38.8M | 33.1M | 29.5M | 21.3M |
| Operating Expenses | |||||
| R&D Expense | 6.5M | 6.3M | 5.4M | 4.9M | 9.9M |
| SG&A Expense | 48.4M | 46.6M | 41.4M | 47.4M | 52.0M |
| General & Admin Expense | — | — | 40.0M | 45.9M | — |
| Selling & Marketing Expense | — | — | 1.4M | 1.5M | — |
| Other Expenses | — | — | — | — | 5.5M |
| Total Operating Expenses | 54.9M | 52.9M | 46.7M | 52.3M | 67.4M |
| Cost and Expenses | 84.3M | 80.6M | 69.3M | 75.4M | 91.6M |
| Operating Income (EBIT) | (13.2M) | (14.1M) | (13.6M) | (22.8M) | (46.1M) |
| Non-Operating | |||||
| Interest Income | 767.0K | 289.0K | 767.0K | 1.5M | 830.0K |
| Interest Expense | 5.1M | 4.3M | 2.2M | 2.3M | 2.4M |
| Net Interest Income | (4.3M) | (4.0M) | (1.5M) | (819.0K) | (1.6M) |
| Other Non-Op Income/Expense | (5.7M) | (5.8M) | (1.5M) | (819.0K) | (1.6M) |
| Non-Operating Income (excl Interest) | 548.0K | 1.5M | (767.0K) | (1.5M) | (830.0K) |
| EBT (Pre-Tax Income) | (18.9M) | (19.9M) | (15.1M) | (23.7M) | (47.7M) |
| Income Tax Expense | 50.0K | 51.0K | 12.0K | 33.0K | (282.0K) |
| Bottom Line | |||||
| Net Income | (18.9M) | (20.0M) | (15.1M) | (23.7M) | (47.4M) |
| Earnings from Cont. Ops | (18.9M) | (20.0M) | (15.1M) | (23.7M) | (47.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (18.9M) | (20.0M) | (15.1M) | (23.7M) | (47.4M) |
| Per Share | |||||
| Basic EPS | ($0.82) | ($0.93) | ($0.83) | ($1.34) | ($2.77) |
| Diluted EPS | ($0.82) | ($0.93) | ($0.83) | ($1.34) | ($2.77) |
| Revenue Per Share | $2.94 | $3.09 | $3.06 | $2.97 | $2.67 |
| Shares | |||||
| Basic Shares Outstanding | 24.2M | 21.6M | 18.2M | 17.7M | 17.1M |
| Diluted Shares Outstanding | 24.2M | 21.6M | 18.2M | 17.7M | 17.1M |
| Profitability Metrics | |||||
| EBITDA | (11.5M) | (13.5M) | (11.1M) | (19.2M) | (43.7M) |
| D&A | 2.3M | 2.1M | 1.7M | 2.2M | 1.6M |
| EBIT | (13.8M) | (15.6M) | (12.9M) | (21.3M) | (45.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026